1. Home
  2. XBIT vs PDSB Comparison

XBIT vs PDSB Comparison

Compare XBIT & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.35

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

HOLD

Current Price

$1.06

Market Cap

62.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
PDSB
Founded
2005
2005
Country
United States
United States
Employees
N/A
10
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.4M
62.0M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
XBIT
PDSB
Price
$2.35
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
26.1K
1.2M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.09
$0.51
52 Week High
$3.61
$1.85

Technical Indicators

Market Signals
Indicator
XBIT
PDSB
Relative Strength Index (RSI) 39.19 47.29
Support Level $2.35 $0.82
Resistance Level $2.41 $1.12
Average True Range (ATR) 0.06 0.13
MACD -0.01 -0.02
Stochastic Oscillator 13.79 25.77

Price Performance

Historical Comparison
XBIT
PDSB

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

Share on Social Networks: